标题
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
作者
关键词
-
出版物
Frontiers in Oncology
Volume 10, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2020-03-12
DOI
10.3389/fonc.2020.00343
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment
- (2019) Alice Guazzelli et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial
- (2019) Arnaud Scherpereel et al. LANCET ONCOLOGY
- Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial
- (2019) Maria J Disselhorst et al. Lancet Respiratory Medicine
- Enhancing Dendritic cell Therapy in Solid Tumors with Immune Modulating Conventional Treatment
- (2019) R.A. Belderbos et al. Molecular Therapy-Oncolytics
- Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent.
- (2019) Prasad S. Adusumilli et al. JOURNAL OF CLINICAL ONCOLOGY
- Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy
- (2019) Raffit Hassan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial
- (2019) Nadine L de Boer et al. BMJ Open
- Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial
- (2019) Giorgio V Scagliotti et al. Lancet Respiratory Medicine
- Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy for Treatment of Malignant Pleural Mesothelioma
- (2019) Raffit Hassan et al. CLINICAL CANCER RESEARCH
- Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase 2 study in malignant pleural mesothelioma (MERIT)
- (2019) Morihito Okada et al. CLINICAL CANCER RESEARCH
- CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab
- (2019) Andre Kunert et al. Journal for ImmunoTherapy of Cancer
- A multicenter, randomized, phase II/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial
- (2019) Robert A. Belderbos et al. Translational Lung Cancer Research
- LBA91_PRA multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial
- (2019) S Popat et al. ANNALS OF ONCOLOGY
- LBA92Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)
- (2019) S A Burgers et al. ANNALS OF ONCOLOGY
- 1843OSAKK 17/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial
- (2019) Y Metaxas et al. ANNALS OF ONCOLOGY
- Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial
- (2019) Giovanni L Ceresoli et al. LANCET ONCOLOGY
- Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge
- (2018) Luana Calabrò et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol
- (2018) Nobukazu Fujimoto et al. Clinical Lung Cancer
- PD-1 blockade with nivolumab in patients with recurrent Malignant Pleural Mesothelioma
- (2018) Josine Quispel-Janssen et al. Journal of Thoracic Oncology
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of intracavitary therapies in the treatment of malignant pleural mesothelioma
- (2018) Pietro Bertoglio et al. Journal of Thoracic Disease
- A phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers.
- (2018) Kwang-Yu Chang et al. JOURNAL OF CLINICAL ONCOLOGY
- CDK4/6 inhibitor and radiation therapy in malignant pleural mesothelioma.
- (2018) Seiji Matsumoto et al. JOURNAL OF CLINICAL ONCOLOGY
- DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results.
- (2018) Anna K. Nowak et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.
- (2018) Marjorie Glass Zauderer et al. JOURNAL OF CLINICAL ONCOLOGY
- SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma.
- (2018) Anne S. Tsao et al. JOURNAL OF CLINICAL ONCOLOGY
- Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma
- (2018) Yannis Metaxas et al. Journal of Thoracic Oncology
- Scientific Advances and New Frontiers in Mesothelioma Therapeutics
- (2018) Luciano Mutti et al. Journal of Thoracic Oncology
- CBMT-29. INDUCTION OF AUTOPHAGY FOLLOWING TTFIELDS APPLICATION SERVES AS A SURVIVAL MECHANISM MEDIATED BY AMPK ACTIVATION
- (2018) Anna Shteingauz et al. NEURO-ONCOLOGY
- Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy
- (2018) Mandy van Gulijk et al. Frontiers in Immunology
- Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets?
- (2018) Anne Huber et al. Frontiers in Immunology
- Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers
- (2017) Emma Beddowes et al. JOURNAL OF CLINICAL ONCOLOGY
- Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial
- (2017) Federica Grosso et al. JOURNAL OF CLINICAL ONCOLOGY
- The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC
- (2017) Christian Manegold et al. Journal of Thoracic Oncology
- Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial
- (2017) Michele Maio et al. LANCET ONCOLOGY
- Oncolytic Viral Therapy for Mesothelioma
- (2017) Daniel F. Pease et al. Frontiers in Oncology
- Oncolytic viruses: finally delivering
- (2016) Leonard W Seymour et al. BRITISH JOURNAL OF CANCER
- CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma
- (2016) M. Betti et al. CANCER LETTERS
- Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2016) S. O. Dolly et al. CLINICAL CANCER RESEARCH
- Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFN Combined with Chemotherapy
- (2016) D. H. Sterman et al. CLINICAL CANCER RESEARCH
- Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
- (2016) Andrea Schietinger et al. IMMUNITY
- Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma
- (2016) Andreas Rimner et al. JOURNAL OF CLINICAL ONCOLOGY
- A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical and Translational Outcomes
- (2016) Wieneke A. Buikhuisen et al. Journal of Thoracic Oncology
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
- (2016) Gérard Zalcman et al. LANCET
- Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations
- (2016) Raphael Bueno et al. NATURE GENETICS
- High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma
- (2016) Yoshie Yoshikawa et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
- (2016) Vinit Kumar et al. TRENDS IN IMMUNOLOGY
- Inherited Mutations in Women With Ovarian Carcinoma
- (2016) Barbara M. Norquist et al. JAMA Oncology
- Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) P. Baas et al. ANNALS OF ONCOLOGY
- Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of Cancer
- (2015) Jill A. Ohar et al. CANCER RESEARCH
- Targeting immune checkpoints: New opportunity for mesothelioma treatment?
- (2015) Elly Marcq et al. CANCER TREATMENT REVIEWS
- Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity
- (2015) Alan Serrels et al. CELL
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
- (2015) Steven J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study
- (2015) Marco Lo Iacono et al. Journal of Thoracic Oncology
- CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans
- (2015) G. Eilers et al. MOLECULAR CANCER THERAPEUTICS
- Loss of BAP1 function leads to EZH2-dependent transformation
- (2015) Lindsay M LaFave et al. NATURE MEDICINE
- Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer
- (2015) Manish R. Patel et al. Oncotarget
- The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers
- (2015) Hideki Ujiie et al. OncoImmunology
- Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)
- (2015) Susana Cedrés et al. PLoS One
- Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
- (2014) S Zhou et al. BRITISH JOURNAL OF CANCER
- Asbestos: use, bans and disease burden in Europe
- (2014) Takashi Kameda et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Whole-Exome Sequencing Reveals Frequent Genetic Alterations in BAP1, NF2, CDKN2A, and CUL1 in Malignant Pleural Mesothelioma
- (2014) G. Guo et al. CANCER RESEARCH
- Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Chemonaive Patients With Unresectable Malignant Pleural Mesothelioma
- (2014) Anne S. Tsao et al. Clinical Lung Cancer
- B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis
- (2014) Aaron Scott Mansfield et al. Journal of Thoracic Oncology
- Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma
- (2014) Robin Cornelissen et al. PLoS One
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
- (2014) P. S. Adusumilli et al. Science Translational Medicine
- Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study
- (2014) Mariam Jamal-Hanjani et al. PLOS BIOLOGY
- Therapies currently in Phase II trials for malignant pleural mesothelioma
- (2013) Giulia Pinton et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1
- (2013) Giulia Pinton et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Phase 2 Study of Sorafenib in Malignant Mesothelioma Previously Treated with Platinum-Containing Chemotherapy
- (2013) Sophie Papa et al. Journal of Thoracic Oncology
- Microenvironmental regulation of tumor progression and metastasis
- (2013) Daniela F Quail et al. NATURE MEDICINE
- Deciphering Signatures of Mutational Processes Operative in Human Cancer
- (2013) Ludmil B. Alexandrov et al. Cell Reports
- Dendritic cell-based immunotherapy in mesothelioma
- (2012) Robin Cornelissen et al. Immunotherapy
- Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
- (2012) Kelly L. Bolton JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma
- (2012) Loïc Lang-Lazdunski et al. Journal of Thoracic Oncology
- Malignant Pleural Mesothelioma: From the Bench to the Bedside
- (2012) P. Astoul et al. RESPIRATION
- A Trial of Intrapleural Adenoviral-mediated Interferon-α2b Gene Transfer for Malignant Pleural Mesothelioma
- (2011) Daniel H. Sterman et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
- (2011) Gottfried E. Konecny et al. CLINICAL CANCER RESEARCH
- Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
- (2011) Da Yang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
- (2011) Tom Treasure et al. LANCET ONCOLOGY
- Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma
- (2011) Giovanni L. Ceresoli et al. LUNG CANCER
- The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma
- (2011) Matthew Bott et al. NATURE GENETICS
- Germline BAP1 mutations predispose to malignant mesothelioma
- (2011) Joseph R Testa et al. NATURE GENETICS
- Consolidative Dendritic Cell-based Immunotherapy Elicits Cytotoxicity against Malignant Mesothelioma
- (2010) Joost P. Hegmans et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Gene Therapy for Mesothelioma and Lung Cancer
- (2010) Anil Vachani et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection
- (2010) Noriyuki Yamada et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer
- (2010) Barbara Delage et al. INTERNATIONAL JOURNAL OF CANCER
- A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307
- (2010) Sarita Dubey et al. Journal of Thoracic Oncology
- Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
- (2010) W. R. Wiedemeyer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Vascular Endothelial Growth Factor Receptor 2 Mediates Macrophage Infiltration into Orthotopic Pancreatic Tumors in Mice
- (2008) S. P. Dineen et al. CANCER RESEARCH
- Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients
- (2008) Raja M. Flores et al. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started